138 related articles for article (PubMed ID: 12037155)
1. Can we change the course of beta-cell destruction in type 1 diabetes?
Gale EA
N Engl J Med; 2002 May; 346(22):1740-2. PubMed ID: 12037155
[No Abstract] [Full Text] [Related]
2. Type 1 diabetes--does suppressing T cells increase insulin?
Lernmark A
N Engl J Med; 2005 Jun; 352(25):2642-4. PubMed ID: 15972873
[No Abstract] [Full Text] [Related]
3. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.
Keymeulen B; Vandemeulebroucke E; Ziegler AG; Mathieu C; Kaufman L; Hale G; Gorus F; Goldman M; Walter M; Candon S; Schandene L; Crenier L; De Block C; Seigneurin JM; De Pauw P; Pierard D; Weets I; Rebello P; Bird P; Berrie E; Frewin M; Waldmann H; Bach JF; Pipeleers D; Chatenoud L
N Engl J Med; 2005 Jun; 352(25):2598-608. PubMed ID: 15972866
[TBL] [Abstract][Full Text] [Related]
4. [Clinical study of the month. Attempt at preservation of B cells during the initial phase of type 1 diabetes: negative results with ultralente insulin, but promising results with an anti-CD3 monoclonal antibody].
Philips JC; Scheen AJ;
Rev Med Liege; 2002 Jun; 57(6):413-7. PubMed ID: 12180038
[TBL] [Abstract][Full Text] [Related]
5. [Antibodies instead of insulin?].
Anders S; Kühnemund L; Stauch M; Zündorf I; Dingermann T
Pharm Unserer Zeit; 2010 Mar; 39(2):97-8. PubMed ID: 20196056
[No Abstract] [Full Text] [Related]
6. Anti-CD3 antibodies for type 1 diabetes: beyond expectations.
Bach JF
Lancet; 2011 Aug; 378(9790):459-60. PubMed ID: 21719098
[No Abstract] [Full Text] [Related]
7. Mechanisms mediating anti-CD3 antibody efficacy: insights from a mathematical model of type 1 diabetes.
Young DL; Ramanujan S; Kreuwel HT; Whiting CC; Gadkar KG; Shoda LK
Ann N Y Acad Sci; 2006 Oct; 1079():369-73. PubMed ID: 17130581
[TBL] [Abstract][Full Text] [Related]
8. Immune intervention with anti-CD3 in diabetes.
Harlan DM; von Herrath M
Nat Med; 2005 Jul; 11(7):716-8. PubMed ID: 16015359
[No Abstract] [Full Text] [Related]
9. The use of CD3-specific antibodies in autoimmune diabetes: a step toward the induction of immune tolerance in the clinic.
Chatenoud L
Handb Exp Pharmacol; 2008; (181):221-36. PubMed ID: 18071948
[TBL] [Abstract][Full Text] [Related]
10. Lessons from type 1 diabetes for understanding natural history and prevention of autoimmune disease.
Simmons K; Michels AW
Rheum Dis Clin North Am; 2014 Nov; 40(4):797-811. PubMed ID: 25437293
[TBL] [Abstract][Full Text] [Related]
11. Clinical studies. Trying to reset the clock on type 1 diabetes.
Couzin-Frankel J
Science; 2011 Aug; 333(6044):819-21. PubMed ID: 21835995
[No Abstract] [Full Text] [Related]
12. Anti-CD3/Anti-CXCL10 Antibody Combination Therapy Induces a Persistent Remission of Type 1 Diabetes in Two Mouse Models.
Lasch S; Müller P; Bayer M; Pfeilschifter JM; Luster AD; Hintermann E; Christen U
Diabetes; 2015 Dec; 64(12):4198-211. PubMed ID: 26293506
[TBL] [Abstract][Full Text] [Related]
13. A case of anti-islet-antibody-positive patient treated with insulin plus calcitriol.
Cetinkalp S; Hamulu F; Ozgen AG; Kavalali I; Kabalak T; Yilmaz C; Tüzün M
Endocr J; 1999 Dec; 46(6):837-8. PubMed ID: 10724361
[No Abstract] [Full Text] [Related]
14. Clinical trials. Diabetes' brave new world.
Couzin J
Science; 2003 Jun; 300(5627):1862-5. PubMed ID: 12817117
[No Abstract] [Full Text] [Related]
15. Prevention versus intervention of type 1 diabetes.
Brooks-Worrell B; Palmer JP
Clin Immunol; 2013 Dec; 149(3):332-8. PubMed ID: 23803322
[TBL] [Abstract][Full Text] [Related]
16. [Monoclonal antibodies in diabetes: almost approaching the dream?].
Philips JC; Keymeulen B; Mathieu C; Scheen AJ
Rev Med Liege; 2009; 64(5-6):327-33. PubMed ID: 19642469
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody.
Ishikawa H; Ochi H; Chen ML; Frenkel D; Maron R; Weiner HL
Diabetes; 2007 Aug; 56(8):2103-9. PubMed ID: 17456848
[TBL] [Abstract][Full Text] [Related]
18. Insulin treatment and type 1 diabetes topics.
Bloomgarden ZT
Diabetes Care; 2006 Apr; 29(4):936-44. PubMed ID: 16567845
[No Abstract] [Full Text] [Related]
19. [One step towards restoration of self-tolerance in human autoimmune diseases].
Chatenoud L
Med Sci (Paris); 2007 Feb; 23(2):167-71. PubMed ID: 17291426
[TBL] [Abstract][Full Text] [Related]
20. Delay of type I diabetes in high risk, first degree relatives by parenteral antigen administration: the Schwabing Insulin Prophylaxis Pilot Trial.
Füchtenbusch M; Rabl W; Grassl B; Bachmann W; Standl E; Ziegler AG
Diabetologia; 1998 May; 41(5):536-41. PubMed ID: 9628270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
